Effects of carvedilol on plasma norepinephrine and myocardial IL-6 production in murine model with the coxsackievirus B3-induced viral myocarditis

Abstract

Abstract: AIM: To examine the effects of carvedilol on plasma norepinephrine and myocardial IL-6 production in murine model with the coxsackievirus B3 (CVB3)-induced viral myocarditis.METHODS: Eighty male BALB/C mice were divided into three groups randomly, including normal group, carvedilol group, myocarditis group. The latter two groups were intraperitoneally inoculated with CVB3. Starting 24 h after infection carvedilol was administered orally in a dose of 10 mg·kg^-1·d^-1 for 14 days continuously. Myocarditis group and normal group were used with same dose PBS. Eight mice who were randomly taken from each groups were killed on day 7 or 14. Myocardial histopathology changes, the heart weight/body weight ratio, the plasma norepinephrine, the mRNA and protein expression of myocardial IL-6 were studied.RESULTS: Carvedilol significantly attenuated myocardial lesions and decreased the heart weight/body weight ratio(P<0.05). The plasma norepinephrine was decreased, the mRNA and protein expression of IL-6 was down regulated remarkably in the carvedilol group compared with the myocarditis group(P<0.05).CONCLUSION: Carvedilol protects against CVB3-induced viral myocarditis in mice. Carvedilol exerts some of its beneficial effects by decreasing the plasma catecholamine levels and down-regulating the expression of IL-6.

Key words: Carvedilol, Norepinephrine, IL-6, Viral myocarditis

CLC Number:

R965.2

LV Gan-xin, ZHANG Teng, ZHOU Na-dan, CHEN Yi-he, GE Li-Sha, LI Yue-chun. Effects of carvedilol on plasma norepinephrine and myocardial IL-6 production in murine model with the coxsackievirus B3-induced viral myocarditis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1332-1337.

References

[1] Cooper LT Jr. Myocarditis[J]. N Engl J Med, 2009, 360(15): 1526-1538.
[2] Yajima T, Knowlton KU. Viral myocarditis: from the perspective of the virus[J]. Circulation, 2009, 119(19): 2615-2624.
[3] Tanaka T, Kanda T, McManus BM, et al. Overexpression of interleukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-α[J]. J Mol Cell Cardiol, 2001, 33(9): 1627-1635.
[4] Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac beta-adrenergic receptors, and heart failure[J]. Circulation, 2000, 101(14): 1634-1637.
[5] Van der Poll T, Coyle SM, Barbosa K, et al. Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin-10 production during humane ndotoxemia[J]. J Clin Invest, 1996, 97(3): 713-719.
[6] Dulin B, Abraham WT. Pharmacology of carvedilol[J]. Am J Cardiol, 2004, 93(Suppl): 3B-6B.
[7] Yue-Chun L, Li-Sha G, Jiang-Hua R, et al. Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis[J]. J Cardiovasc Pharmacol, 2008, 51(1): 92-98.
[8] 李岳春,陈鹏,革丽莎,等. 卡维地洛和美托洛尔对病毒性心肌炎小鼠IL-12与IFN-γ表达水平的影响[J]. 中国临床药理学与治疗学,2009, 14(10): 1101-1105.
[9] Nishio R, Shioi T, Sasayama S, et al. Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus[J]. J Am Coll Cardilol, 2003, 41(2): 340-345.
[10] Pauschinger M, Rutschow S, Chandrasekharan K, et al. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response[J]. Eur J Heart Fail, 2005, 7(4): 444-452.
[11] Li YC, Ge LS, Yang PL, et al. Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction[J]. Eur J Pharmacol, 2010, 640(1/2/3): 112-116.
[12] Tschöpe C, Westermann D, Steendijk P, et al. Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis:effect of carvedilol and metoprolol[J]. EUR J Pharmacol, 2004, 491(2/3): 173-179.
[13] Yue-chun L, Li-sha G, Xue-qiang G, et al. The mechanism of carvedilol in experimental viral myocarditis[J]. Curr Pharm Des, 2012, 18(12): 1620-1624.
[14] Feuerstein G, Yue TL, Ma X, et al. Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol[J]. Prog Cardiovasc Dis, 1998, 41(1 Suppl 1): 17-24.
[15] Cook-Mills JM, Cohen RL, Perlman RL, et al. Inhibition of lymphocyte activation by catecholamines: evidence for a non-classical mechanism of catecholamine action[J]. Immunology, 1995, 85(4): 544-549.
[16] Madden KS, Felten DL. Experimental basis for neural-immune interactions[J]. Physiol Rev, 1995, 75(1): 77-106.
[17] Wang JF, Meissner A, Malek S, et al. Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis[J]. Am J Physiol, 2005, 289(4): H1577-1583.